Last updated on November 2017

AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC# 617807)


Brief description of study

AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC# 617807)

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00557193?term=AALL0631&rank=1

Clinical Study Identifier: TX13364

Contact Investigators or Research Sites near you

Start Over

Patricia Green

Memorial Health University Medical Center
Savannah, GA USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.